IL6 and COVID-19: The systemic multi-centric studies with inclusion of inflammatory and coagulopathy biomarkers (e.g. IL-6, TNF-α, d-dimer, C1q) need to be conducted at the country level to validate findings of this study and to gain new insights into the prevalence and prognostic impact of DM in Indian COVID-19 patients.